Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Independent directors’ opinions on the 11th meeting of the 4th board of directors
Independent opinions on relevant matters
In accordance with the guiding opinions on the establishment of independent director system in listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies, the articles of association, the working system of independent directors of the company and the relevant provisions of relevant laws and regulations, As an independent director of Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as “the company”), based on objective and independent judgment, we hereby express the following independent opinions on the relevant matters considered at the 11th meeting of the Fourth Board of directors of the company:
1、 Independent opinions on changing the commitment subject of some senior managers to increase their shares in the company
After review, we believe that this change of commitment is in line with the actual situation, conducive to ensuring the substantive performance of the commitment, in line with the provisions of laws, regulations and normative documents such as the guidelines for the supervision of listed companies No. 4 – commitments of listed companies and their related parties of the CSRC, and there is no damage to the interests of the company and all shareholders.
Therefore, we unanimously agree to this change of commitment and agree to submit it to the general meeting of shareholders for deliberation.
2、 Independent opinions on the transfer of development expenditure to expense and the provision for asset impairment
After verification, we believe that the transfer of R & D project development expenditure to expense and the provision for asset impairment comply with the accounting standards for business enterprises and other relevant regulations, reflect the principle of accounting prudence, comply with the actual situation of the company, and can more truly reflect the financial status and asset value of the company.
Therefore, we unanimously agree on the transfer of development expenditure to expense and the provision for asset impairment. (no text below)
(page 436 of the main body of the 11th session of the independent board of directors: no signature)
Ren Hong, Chen Mingyu, Qiang Xinrong
Fujian Cosunter Pharmaceutical Co.Ltd(300436) board of directors date, 2022
